Document:

LICENSE AGREEMENT 

        This
License Agreement (this “Agreement”) is entered into and made effective as of
December 1, 2006, by George Andrew Eby III, (“EBY”) and Auriga Laboratories,
Inc., a Delaware corporation (“AURIGA”) with respect to the facts set forth
below. 

RECITALS 

        A.                 EBY
has developed certain products and technology relating to the treatment of           the
common cold with zinc and has obtained certain patents relating to the
          treatment of the common cold with zinc.  

        B.                 AURIGA
is engaged in research and development of, among other things,           pharmaceutical
products intended for the treatment of the common cold and           pharmaceutical
products containing zinc acetate.  

        C.                 EBY
desires to grant to AURIGA, and AURIGA wishes to acquire, a worldwide right           and
license to EBY’s products, technology and patents.  

AGREEMENT 

        NOW,
THEREFORE, in consideration of the mutual covenants and conditions set forth herein, EBY
and AURIGA hereby agree as follows: 

    1.    Definitions.  Capitalized
terms shall have the meaning set forth below.  

            1.1    “Affiliate”shall
mean any entity which directly or indirectly controls, is controlled by or is under
common control with AURIGA. The term “control” as used herein means the
possession of the power to direct or cause the direction of the management and the
policies of an entity, whether through the ownership of a majority of the outstanding
voting securities or by contract or otherwise.  

            1.2    “Combination
Product” shall mean a product containing a Licensed Product together with one or
more other active ingredients, devices, products, equipment or components that are
themselves not Licensed Products. 

            1.3    “Commercial
Launch” shall mean the initial commercial sale of a Licensed Product by AURIGA or
a third party authorized to sell products on behalf of AURIGA. 

            1.4    “Confidential
  Information”   shall  mean  any  and  all  proprietary  or  confidential information of
EBY or AURIGA which may be exchanged between the parties at any time and from time to
time during the term of this Agreement. Information shall not be considered confidential
to the extent that it: 

	 	        1.4.1    Is
publicly disclosed through no fault of any party hereto, either before or after it becomes
known to the receiving party; or 

Page 1 of 10 

	 	        1.4.2    Was
known to the receiving party prior to the date of this Agreement, which knowledge
was acquired independently and not from another party hereto (or such party’s
employees); or   

	 	        1.4.3    Is  subsequently
disclosed  to the  receiving  party in good  faith by a third party
who has a right to make such disclosure; or 

	 	        1.4.4    Has
been published by a third party as a matter of right.  

            1.5    “Developed
Technology”  shall  mean   intellectual   property  and  technical know-how, including
all rights in discoveries, knowledge, experience, improvements, processes, products,
reports, models, codes, inventions, works of authorship, trade secrets, pending patent
applications, patents, copyrights, or other proprietary information (whether or not
patentable, copyrightable or the subject of any other type of intellectual property
protection) that is discovered or developed by AURIGA, including, without limitation, any
of the foregoing that is based or incorporates any EBY Technology.  

            1.6    “Existing
Licenses” shall mean the non-exclusive license agreements EBY has entered into
with F&F Foods and Weider Nutrition, respectively. 

            1.7    “Licensed
Product”  shall mean any product  which  cannot be  developed,  manufactured, used or
sold without (i) infringing one or more claims under EBY Technology or (ii) utilizing any
part of EBY Technology.  

            1.8    “EBY
Technology” shall mean all intellectual property and technical know-how,
including all rights in discoveries, knowledge, experience, improvements, processes,
products, reports, models, codes, inventions, works of authorship, trade secrets, pending
patent applications, patents, including without limitation, the following patents: U.S.
Patent 5,409,905 (as revised by Re-Examination SN90/004,518); 5,095,035; 5,002,970; and
4,956,385; and Canadian Patent 2,099,670, copyrights, or other proprietary information
(whether or not patentable, copyrightable or the subject of any other type of intellectual
property protection) that is owned by EBY concerning zinc and the common cold. In
addition, “Ideas and Inventions” developed under that certain Consulting
Agreement, by and between Eby and Auriga, dated as of the date hereof (the
“Consulting Agreement”), as that term is defined in the Consulting Agreement,
shall be included within “Eby Technology.” 

            1.9    “Manufacturing
Instructions” shall mean the technology, trade secrets, know-how and other
proprietary information and other information used for the manufacture, packaging, release
testing, validation, stability and shelf life of Licensed Products that are in existence
and in the possession of, under the control of, or accessible to, the EBY as of the date
of this Agreement, including, without limitation, all (i) current manufacturing processes,
(ii) current test methods, (iii) current specifications for raw materials, (iii) current
manufacturing and packaging instructions, (iv) the most recently available chemical,
pharmacological, toxicological, safety, quality control and clinical data, (iv) current
master formulae, (v) validation reports, (vi) stability data, (vii) analytical methods,
(viii) records of complaints from the twenty-four (24) month period ending as of the date
of this Agreement, (ix) annual product reviews from the prior twenty four (24) months, and
(x) other master documents necessary for the manufacture, control and release of Licensed
Products as conducted by, or on behalf of, EBY. 

Page 2 of 10 

            1.10    “Net
Sales” shall mean the gross amount invoiced by AURIGA, or its Affiliates and
Sub-licensees, or any of them, on all sales of Licensed Products less (i) actual returns
and actual credits taken, (ii) freight, postage, and shipping expenses (including
insurance relating thereto) absorbed by Auriga; and (iii) sales and other excise taxes,
tariffs, customs duties or other duty and any other governmental charges. For purposes of
determining Net Sales, a sale shall be deemed to have occurred when an invoice therefore
shall be generated or the Licensed Product shipped for delivery. Only sales of Licensed
Products by AURIGA, or an Affiliate or Sub-licensee of AURIGA to unrelated parties shall
be deemed Net Sales hereunder. If the Licensed Product is sold in the form of a
Combination Product, then for the purpose of calculating royalties owed under this
Agreement on sales of the Combination Product, Net Sales shall mean an amount equal to the
actual net sales of such Combination Product (calculated using the method described above)
multiplied by the fraction A/(A+B), where A is the weighted (by sales volume) average
invoice price of the actual Licensed Product component of such Combination Product, and B
is the total of the weighted (by sales volume) average invoice prices of the other
products, active ingredients, devices, equipment or components of such Combination
Product. 

            1.11    “Product
Marketing Materials” shall mean all marketing materials used solely and
specifically with respect to Licensed Products that are in existence as of the date of
this Agreement, to the extent such materials are within the possession of EBY and are
legally permitted to be assigned, including all advertising and display materials, product
data, price lists, sales materials, marketing information, marketing plans, sales,
training and education materials, promotional materials, scientific and commercial
publications, market research, artwork for the production of packaging components and
other materials associated solely and specifically with Licensed Products that EBY has the
right to transfer. 

            1.12    “Regulatory
Documentation”  shall mean  copies of any and all  dossiers  and  packages, labels and
regulatory certificates, any correspondence with the U.S. Food and Drug Administration,
or any other regulatory bodies, drug reports, periodic safety update reports, medical
inquiries and standard communication letters relating to Licensed Products. 

            1.13    “Sourcing
Documentation” shall mean all copies of any  documentation  and  information under the
possession of, or reasonably accessible to, EBY relating to sourcing of raw materials and
necessary to manufacture Licensed Products.  

            1.14    “Technical
Information” shall mean all technical, scientific, chemical, biological,
pharmacological, and toxicological data generated specifically for Licensed Products,
other than the Manufacturing Information, that are in existence as of the date of this
Agreement, to the extent such materials are within the possession or control of, or
accessible to, EBY. 

    2.    License
Terms and Conditions. 

            2.1    Grant
of License. 

                      2.1.1    Subject
to the Existing  Licenses,  EBY hereby grants to AURIGA an exclusive,  worldwide license,
including the right to sublicense, to the EBY Technology, to make, to have made, to use,
and to sell Licensed Products, subject to the terms of this Agreement. In addition, the
license granted to Auriga pursuant to this Section 2.1.1 shall be exclusive even as to
Eby, but such exclusivity even as to Eby shall continue only while that certain
Consulting Agreement (as defined in Section 1.8 hereof) remains in effect. 

Page 3 of 10 

                      2.1.2    Upon
execution of this Agreement, EBY shall provide to AURIGA, without charge (other than the
royalties payable pursuant to Section 2.4 below), copies of any and all Manufacturing
Instructions, Product Marketing Materials, Regulatory Documentation, Sourcing
Documentation and Technical Information and all embodiments, including, without
limitation, documents, writings and other media, of EBY Technology. 

                      2.1.3    EBY
shall promptly disclose to AURIGA in writing, without charge (other than the royalties
payable pursuant to Section 2.4 below), any improvements upon EBY Technology made during
the term of this Agreement, and shall deliver to AURIGA any and all embodiments,
including, without limitation, documents, writings and other media, of such improvements. 

            2.2    Ownership.    The
patent applications filed and the patents obtained by AURIGA pursuant to
          Section 4.1 hereof, all Combination Products and all Developed Technology shall
          be owned solely by AURIGA.  

            2.3    Sublicense.     AURIGA
shall have the right to grant sublicenses to any party with respect to           the
rights conferred upon AURIGA under this Agreement upon notification to EBY           of
the identity of said sublicenses.  

            2.4    Royalties. 

            2.4.1  Initial Royalties. In partial consideration for the exclusive license granted
pursuant to Section 2.1 hereof, AURIGA shall pay to EBY a nonrefundable royalty ninety
days after the Commercial Launch by AURIGA of a Licensed Product developed or sold by
AURIGA in the amount of Fifty Thousand United States (U.S.) Dollars ($50,000). The royalty
described in this Section 2.4.1 is consideration for the grant and continuation of the
license hereunder. 

            2.4.2  Percentage
Royalties. As additional consideration for the exclusive license granted
pursuant to Section 2.1 hereof, AURIGA shall pay to EBY during the term of this Agreement
a continuing royalty in the amount of seven percent (7%) of annual Net Sales of Licensed
Products until such annual Net Sales equal Ten Million U.S. Dollars ($10,000,000) and ten
percent (10%) of all annual Net Sales of Licensed Products thereafter. 

            2.4.3  Royalty
Payable on Combination Products. The royalty to be paid EBY on any
particular Combination Product sold by Auriga or its Affiliates and Sublicensees during
the term of this Agreement shall be the royalty rates set forth in Section 2.4.2. 

            2.4.4  Duration
of Royalty Obligations. Upon the expiration or termination of this
Agreement, whichever is earlier to occur, AURIGA shall have no further obligations to pay
any royalties to EBY except for royalties owed on Licensed Products and/or Combination
Products sold prior to such expiration or termination this Agreement. 

Page 4 of 10 

            2.5    Quarterly
Payments. 

            2.5.1  Sales
by AURIGA.  With regard to Net Sales made by AURIGA or its  Affiliates,  royalties shall
be payable by AURIGA quarterly, within sixty (60) days after the end of each calendar
quarter, based upon the Net Sales of Licensed Products during such preceding calendar
quarter, commencing with the calendar quarter in which the Commercial Launch of any
Licensed Product occurs.  

            2.5.2  Sales
by  Sub-licensees.  With  regard to Net Sales made by  Sub-licensees  of AURIGA or its
Affiliates, royalties shall be payable by AURIGA quarterly, within ninety (90) days after
the end of each calendar quarter, based upon the Net Sales of Licensed Products by such
Sub-licensee during such preceding calendar quarter, commencing with the calendar quarter
in which the Commercial Launch of any Licensed Product occurs by such Sub-licensee.  

            2.6    Reports.  AURIGA
shall furnish to EBY at the same time as each royalty payment is made by
          AURIGA, a detailed written report of Net Sales of the Licensed Products and the
          royalty due and payable thereon, on a product-by-product basis, for the
calendar           quarter upon which the royalty payment is based.  

            2.7    Records.  AURIGA
shall keep, and cause its Affiliates and Sub-licensees to keep, full,           complete
and proper records and accounts of all sales of Licensed Products in           sufficient
detail to enable the royalties payable on Net Sales of each Licensed           Product to
be determined.  

    3.    Inspection
Right. Upon ten (10) days’ prior written  notice and at mutually  agreeable
times, but in no event more than twice every twelve (12) months, EBY shall have the right
to inspect the LICENSEE’s financial records and information relating to the Licensed
Products, solely for the purpose of auditing the quarterly reports referred to in Section
2.6 and the payments under Section 2.5 with respect to the calculation of the royalties
referred to in Section 2.4.  

    4.    Patent
Matters. 

            4.1    Patent
Prosecution and Maintenance. From and after the date of this Agreement, the provisions
of this Section 4 shall control the prosecution and maintenance of any patent included
within EBY Technology. Subject to the requirements, limitations and conditions set forth
in this Agreement, AURIGA shall direct and control, at its own expense (i) the
preparation, filing and prosecution of the United States and foreign patent applications
within EBY Technology (including any interferences and foreign oppositions) and (ii)
maintain the patents issuing therefrom. AURIGA shall select the patent attorney. 

            4.2    Infringement
Actions. 

            4.2.1  Prosecution
 and  Defense of  Infringements.  In order to maintain  the license  granted hereunder in
force, AURIGA shall prosecute any and all infringements of any EBY Technology and shall
defend all charges of infringement arising as a result of the exercise of EBY Technology
by AURIGA, its Affiliates or Sub-licensees, unless otherwise agreed to between EBY and
AURIGA. AURIGA may enter into settlements, stipulated judgments or other arrangements
respecting such infringement, at its own expense. EBY shall permit any action to be
brought in its name if required by law, and AURIGA shall hold EBY harmless from any
costs, expenses and/or liability respecting all such infringements or charges of
infringement. EBY agrees to provide reasonable assistance of a technical or factual
nature which AURIGA may require in any litigation arising in accordance with the
provisions of this section.  

Page 5 of 10 

            4.2.2    Allocation
of Recovery.  Any monetary  damages,  other monetary  recovery or equity from an
infringement action undertaken by AURIGA pursuant to Section 4.2.1 shall first be used to
reimburse the parties for the costs and expenses incurred in such action, and shall
thereafter be treated as Net Sales of a Licensed Product pursuant to which AURIGA shall
have a royalty obligation to EBY pursuant to Section 2.4.2 hereof.  

            4.2.3    Preservation
 of Title.  EBY shall  retain full  ownership  and title to EBY  Technology licensed
hereunder and shall use its reasonable best efforts to preserve and maintain such full
ownership and title, subject to AURIGA fully performing all of its obligations under this
Agreement.  

    5.    Indemnification. 

            5.1    By
AURIGA. AURIGA agrees to defend, indemnify and hold harmless EBY its respective
directors, officers, employees, agents and representatives, from and against any and all
claims, losses, demands, liabilities, obligations and expenses arising from or relating to
any product liability claim asserted by any party as to any Licensed Product or the use of
any EBY Technology by AURIGA pursuant to this Agreement. In any instance in which EBY is
entitled to claim indemnity under the provisions of this Section 5.1, EBY shall have the
right to undertake its own defense and AURIGA shall be responsible for any and all costs
and results of, including settlements and/or judgments resulting from, such defense. 

    6.    Representations
and Warranties of EBY. EBY covenants, represents and warrants that: 

            6.1    the
execution and delivery by EBY of this Agreement will not, and the fulfillment of and
compliance by EBY with the terms, conditions and provisions of this Agreement will not,
conflict with, result in a breach of, constitute a default under (whether with or without
the giving of notice or the lapse of time or both), accelerate or permit the acceleration
of the performance required by, or require any consent, authorization or approval under
any document, instrument, agreement or license to which EBY is a party or is bound; 

            6.2    EBY
is the owner of all EBY Technology and/or has the right to use all EBY Technology, and EBY
has the unrestricted right to grant to AURIGA the right to use all EBY Technology as
provided in this Agreement; 

            6.3    except
as noted in  writing  to AURIGA  prior to the date  hereof  (recited  as the F&F Foods and
Weider non-exclusive licenses), EBY has not assigned, licensed or offered as collateral
any of its rights to EBY Technology; and  

            6.4    AURIGA’s
use of EBY  Technology  will not infringe  upon the  proprietary  rights of any third
party anywhere in the world.  

Page 6 of 10  

    7.    Confidentiality
and Publication. 

            7.1    Treatment
of Confidential Information. The parties agree that during the term of this Agreement,
and for a period of three (3) years after this Agreement terminates, a party receiving
Confidential Information of the other party will (i) maintain in confidence such
Confidential Information to the same extent such party maintains its own proprietary
industrial information, (ii) not disclose such Confidential Information to any third party
without prior written consent of the other party and (iii) not use such Confidential
Information for any purpose except those permitted by this Agreement. 

    8.    Term
and Termination. 

            8.1    Term. Unless
terminated sooner in accordance with the terms set forth herein, this
          Agreement, and the license granted hereunder, shall expire on the earlier to
          occur of (i) March 10, 2009 or (ii) the expiration of U.S. Patent 5,095,035.  

            8.2    Termination
 Upon Default.  Upon the failure of EBY to perform any obligation  required under this
Agreement to be performed by EBY and EBY’s failure to cure such failure to perform
within thirty (30) days after receipt from AURIGA of notice of such failure to perform,
AURIGA may terminate this Agreement upon written notice to EBY. Upon the failure of
AURIGA to perform any obligation required under this Agreement to be performed by AURIGA
and AURIGA’s failure to cure such failure to perform within thirty (30) days after
receipt from EBY of notice of such failure to perform, EBY may terminate this Agreement
upon written notice to AURIGA.  

            8.3    Termination
 Upon  Bankruptcy or Insolvency. This Agreement may be terminated by AURIGA giving
written notice of termination to EBY upon the filing of bankruptcy by AURIGA.  

            8.4    Rights
Upon  Expiration.  Neither  party shall have any  further  rights or  obligations upon
the expiration of this Agreement upon its regularly scheduled expiration date with
respect to this Agreement, other than the obligation of AURIGA to make any and all
reports and payments for the final quarter period; provided, however, that upon such
expiration, AURIGA shall retain the license granted in accordance with this Agreement;
provided further, that upon such expiration, each party shall be required to continue to
abide by its non-disclosure obligations as provided in Section 7.1 and shall continue to
abide by its obligation to indemnify the other party as provided in Section 5.  

            8.5    Rights
Upon  Termination.  Neither  party shall have any further  rights or  obligations upon
the termination of this Agreement prior to its regularly scheduled expiration date with
respect to this Agreement, other than any obligations accrued to the date of such
termination; provided, however, that upon such termination, AURIGA shall retain the
license granted in accordance with this Agreement if circumstances leading to termination
have been resolved, but if circumstances have not been resolved, AURIGA agrees to forfeit
the license and to immediately stop all sales, stop all use and stop all manufacture of
Licensed Products and all Combination Products until the expiration of the Agreement
according to Section 8.4 or pay two and a half times royalties as liquidated damages;
provided further, that upon such termination, each party shall be required to continue to
abide by its non-disclosure obligations as provided in Section 7.1 and shall continue to
abide by its obligation to indemnify the other party as provided in Section 5.  

Page 7 of 10 

    9.    Assignment. Neither
this Agreement nor any rights granted hereunder may be assigned or           transferred
by EBY without the prior written consent of AURIGA. Subject to the           limitations
on assignment herein, this Agreement shall be binding upon and inure           to the
benefit of any successors in interest and assigns of EBY and AURIGA.  

    10.    General
Provisions. 

            10.1    Independent
Contractors. The relationship between EBY and AURIGA is that of independent
contractors. EBY and AURIGA are not joint venturers, partners, principal and agent, master
and servant, employer or employee, and have no other relationship other than independent
contracting parties. EBY and AURIGA shall have no power to bind or obligate each other in
any manner, other than as is expressly set forth in this Agreement. 

            10.2    Dispute
 Resolution.  Any  controversy  or  claim  arising  out of or  relating  to this
Agreement, or the breach thereof, shall be settled by an agreed form of alternative
dispute resolution (ADR), including mediation, arbitration or other form of ADR in
Austin, Texas. If the parties cannot agree on a form of ADR, dispute shall be settled by
binding arbitration in accordance with the Commercial Arbitration Rules of the American
Arbitration Association (“AAA”). Judgment upon the award rendered by the
arbitrators may be enforced in any court having jurisdiction thereof. In the event of an
ADR proceeding between the parties hereto, AURIGA agrees to pay up to $10,000 in the
aggregate for Eby’s actually incurred expenses for said ADR proceedings. Eby
reserves the right to have council of his choice.  

            10.3    Entire
 Agreement;  Modification.  This  Agreement  sets forth the entire  agreement and
understanding between the parties as to the subject matter hereof. This Agreement may be
amended or modified only by a written document signed by both parties.  

            10.4    Applicable
Law.  This Letter shall be governed by the laws of the State of Texas. 

            10.5    Headings. The
headings for each article and section in this Agreement have been inserted           for
convenience of reference only and are not intended to limit or expand on the
          meaning of the language contained in the particular article or section.  

            10.6    Severability. Should
any one or more of the provisions of this Agreement be held invalid or
          unenforceable by a court of competent jurisdiction, it shall be considered
          severed from this Agreement and shall not serve to invalidate the remaining
          provisions thereof. The parties shall make a good faith effort to replace any
          invalid or unenforceable provision with a valid and enforceable one such that
          the objectives contemplated by them when entering this Agreement may be
          realized.  

            10.7    No
Waiver.  Any delay in enforcing a party’s  rights under this  Agreement or any waiver as
to a particular default or other matter shall not constitute a waiver of such party’s
rights to the future enforcement of its rights under this Agreement, excepting only as to
an express written and signed waiver as to a particular matter for a particular period of
time.  

Page 8 of 10  

            10.8    Notices. Any
notices required by this Agreement shall be in writing, shall specifically
          refer to this Agreement and shall be sent by registered or certified airmail,
          overnight courier and shall be forwarded to the respective addresses set forth
          below unless subsequently changed by written notice to the other party:  

	 	
If
to EBY, to:  

	 	
George
A. Eby
                                     14909-C Fitzhugh Road

                                    Austin, Texas 78736

                                    Attention: George Eby

                                    Facsimile: (512) 263-0805 

	 	
If
to AURIGA, to:  

	 	
Auriga
Laboratories, Inc. 
                                    5555 Triangle Parkway

                                    Suite 300

                                    Norcross, Georgia 30092

                                    Attention: Chief Executive Officer

                                    Facsimile: (678) 282-1700 

Notice shall be deemed delivered upon
the date it is deposited into the mail or the date it is delivered to an overnight
courier, as the case may be. 

            10.9    Compliance
with U.S. Laws. Nothing contained in this Agreement shall require or permit EBY or
AURIGA to do any act inconsistent with the requirements of any United States law,
regulation or executive order as the same may be in effect from time to time. 

            10.10    Websites. This
Agreement does not allow, provide for, or require the transfer of control           or
transfer of ownership or sale of any Internet website of EBY to AURIGA.           Nothing
in this Agreement shall be construed to require EBY to transfer, sell or           give
control of any website owned by EBY to AURIGA.  

Page 9 of 10 

        IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth above. 

		
		AURIGA LABORATORIES, INC.
		(“AURIGA”)
		

By: /s/ Philip S. Pesin
		Name: Philip S. Pesin
		Title: Chairman & CEO
		

GEORGE ANDREW EBY III
		(“EBY”)
		

/s/ George Andrew Eby III
		George Andrew Eby III

Page 10 of 10December 1, 2006 

George Andrew Eby III
14909-C
Fitzhugh Road
Austin, Texas, 78736 

	 	Re: 	Consulting
Agreement

Dear Mr. Eby: 

        The
purpose of this letter (“Letter”) is to set forth the terms and
conditions by which you (“Consultant” or “Eby”) will provide
consulting services to Auriga Laboratories, Inc., a Delaware corporation
(“Auriga”), in connection with Auriga’s research and development of
products based on, incorporating or containing zinc acetate (the
“Field”). 

        1.              Consultant
agrees to provide consulting services on an as-needed basis with           respect to
matters related to the Field (“Services”). Services           shall
include, without limitation, providing such advice and information           relating to
the Field as Auriga may reasonably request from time to time.  

        2.              During
the term of this Letter, including any renewal terms, as consideration           for the
Services rendered by Consultant to Auriga under the terms of this           Letter,
Auriga shall compensate Consultant $100,000 annually as follows:  

                (a)              For
the period beginning on December 1, 2006 and ending on the date on which           this
Letter expires pursuant to its terms or is terminated, whichever is first           to
occur, Auriga will pay Consultant a monthly fee in the amount of $2,083.33 in
          accordance with Auriga’s standard payroll policies then in effect; and  

                (b)              For
the period beginning on January 1, 2007 and ending on the date on which this
          Letter expires pursuant to its terms or is terminated, whichever is first to
          occur, Auriga will, on the last day of each calendar quarter and beginning with
          the first calendar quarter of 2007, issue and promptly deliver to Consultant,
or           to a broker of Consultant’s designation, that number of shares of
Auriga           common stock which equals $18,750 of value based upon and valued by the
closing           price of Auriga’s common stock on the day of each such issuance.  

In addition, Auriga will reimburse
Consultant for reasonable and necessary expenses incurred in Consultant’s performance
of Services and approved in advance by Auriga. Such reimbursement shall be contingent on
Consultant adhering to Auriga’s expense reimbursement policies. The foregoing shall
represent Consultant’s sole compensation for the Services to Auriga. 

        3.       Consultant
represents and warrants to Auriga as follows:  

                (a)      Consultant
is free to agree to the terms of this Letter, and Consultant is not           bound by
the terms of any agreement with any previous employer or any other           third party
to refrain from providing consulting services similar to the           Services
Consultant may provide in accordance with the terms of this Letter or           from
using or disclosing any trade secret or confidential or propriety           information
in the course of Consultant’s performance of his obligations           under this
Letter.  

                (b)      Consultant
has not been disqualified or debarred by the U.S. Food and Drug           Administration
for any purpose and has not been charged with or convicted for           conduct relating
to the development, approval or regulation of any drug           products.  

        4.              Consultant
hereby agrees that during the term of this Letter, Consultant will           not directly
or indirectly own, manage, operate, consult, control, invest, or           acquire an
interest in, or otherwise engage or participate in (whether as a           employee,
employer, consultant, advisor or director, or as an owner, investor,           partner,
stockholder, officer, or other participant in) any business that           competes with
Auriga in the Field, including, without limitation, any business           that sells any
products based on, incorporating or containing zinc acetate. This           Section 4
shall not prohibit the ownership of securities of any corporation that           is
listed on a national securities exchange or traded on the national           over-counter
market in an amount that shall not exceed 5% of the outstanding           shares of any
such corporation. Consultant acknowledges that Consultant will           receive valuable
consideration by virtue of this Letter.  

        5.              Except
pursuant to the performance of Services for Auriga or with the consent of
          Auriga, Consultant will not, during the term of this Letter and for a period
          ending two (2) years thereafter, take, disclose, use, sell or otherwise
transfer           any confidential or proprietary information of Auriga or any
subsidiary or           affiliate, including, without limitation, any information Auriga
designates as           confidential, and all techniques, methods, specifications,
processes, selection           of materials, product information, samples, software,
designs, plans, customer           or vendor lists, financial data (including cost and
pricing data), trade secrets           and other customer, sales, financial or business
information, whether or not           patentable, trademarkable or copyrightable,
relating generally or specifically           to Auriga’s business that was or in the
future is supplied to or obtained           by Consultant during the term of this Letter,
so long as such information has           not otherwise been disclosed to the public or
is not otherwise in the public           domain, except as required by law or pursuant to
legal process. Consultant will           return to Auriga, promptly following the
termination or expiration of this           Letter, as the case may be, any information,
documents or materials relating to           Auriga or any subsidiary or affiliate which
came into Consultant’s           possession or control during performance of the
Services.  

        6.              Consultant
will for all purposes be deemed to be an independent contractor and           not an
employee of Auriga. Consultant shall not and shall have no authority to           enter
into negotiations for or enter into any contract or commitments in the           name or
on behalf of Auriga unless explicitly given such authority by Auriga in
          writing.  

        7.              The
term of this Letter shall begin on the date hereof and shall expire on March
          10, 2010; provided, however, that this Letter shall automatically renew for
          successive one-year terms until Auriga provides to Consultant, at least ninety
          (90) daysprior to the expiration of the initial term of this Letter or
          the then current renewal term of this Letter, as the case may be, notice of
          Auriga’s intention not to renew this Letter. In addition, this Letter may
          be terminated as follows:  

2 

	 	        (a)              Upon
written agreement of both parties;  

	 	        (b)              By
Eby immediately upon Auriga filing or having filed against it a petition for
          bankruptcy or other insolvency proceedings;  

	 	        (c)              By
either party in the event of a material breach of this Letter by the other
          party which remains uncured twenty (20) days after written notice of such
          breach; or  

	 	        (d)              By
Auriga, without cause, by providing ninety (90) days prior written notice to
          Consultant.  

	 	        (e)              By
Auriga immediately upon written notice to Consultant in the event that the
          representation and warranty in Section 3(b) above ceases to be true; that
          Consultant is indicted, or otherwise charged with, any felony; that Consultant
          commits an act that brings embarrassment upon Auriga, as determined in
          Auriga’s sole reasonable discretion; or Consultant commits, or is accused
          of committing, an act involving a breach of trust or embezzlement.  

        8.              Auriga
shall fully and completely hold Eby harmless in all circumstances due to           Auriga’s
involvement with Eby and Eby’s patents.  

        9.              Consultant
agrees that all Ideas and Inventions (as defined below) made or           conceived by
Consultant during the term of this Letter shall be deemed to be           included in the
definition of “Eby Technology” in Section 1.8 of that           certain License
Agreement by and among Consultant and Auriga and dated as of the           date hereof.
As used in this Letter, “Ideas and Inventions”          include all
creative work product relating to the Field, including but not           limited to:
ideas; concepts; processes; innovations; improvements; developments;
          discoveries; designs; software; data; data analysis; and data compilations,
etc.           In addition, Auriga shall have a right of first refusal of any patentable
or           patented inventions developed by Consultant outside patents licensed from
Eby by           Auriga.  

        10.              Consultant
shall, in the performance of Services hereunder, fully comply with           all
applicable provisions of laws, regulations, or ordinances, including but not
          limited to the laws of the United States.  

        11.              Nothing
in this agreement shall be construed to require Eby to sell, delete,           surrender,
modify, restrict, give or otherwise loose control of Internet           websites owned by
Eby. The parties agree to work together in good faith to           resolve any issues in
the event that Auriga reasonably believes that content on           any website
controlled by Eby presents regulatory or other legal concerns.  

        12.              At
the end of this Consulting agreement (Letter) and thereafter, Eby shall have
          the right to compete against Auriga in the Field without restriction. This
          clause shall survive the expiration of this agreement.  

        13.              Auriga
and Consultant may amend this Letter only in writing signed by both           parties.
This Letter is the entire agreement between the parties with respect to           the
subject matter hereof. Consultant may not assign this Letter without the           prior
written consent of Auriga. This Letter shall be binding upon and inure to           the
benefit of the parties’ respective successors, permitted assigns and
          personal representatives. This Letter shall be governed by the internal laws of
          the State of Texas (without reference to principles of conflicts of law) and
          subject to mandatory arbitration in Austin, Texas. In the event that any of the
          restrictions contained in Section 4 hereof are found to be invalid or
          unenforceable, the parties agree that the court may reduce the scope, duration
          or breadth of such restriction so as to make the restriction enforceable. In
the           event any other provisions of this Letter are deemed to be invalid or
          unenforceable, such provision shall be stricken and the remaining provisions
          shall not be affected thereby.  

3 

        If
the foregoing correctly sets forth our agreement, please execute the enclosed copy of this
Letter where indicated below and return the original to me. 

		
		Best regards,
		
AURIGA LABORATORIES, INC.
		

By: /s/ Philip S. Pesin
		Name: Philip S. Pesin
		Title: Chairman & CEO

Accepted and agreed to as
of the date
first written above. 

GEORGE A. EBY  

By: /s/ George Andrew Eby
III
             George
Andrew Eby III 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]